DORCAS MWANGI: Open Payments
NPI 1710070842 · DECATUR, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,103 in 120 payments from 14 companies in 2025. Trend: 2023 $895 · 2024 $2,031 · 2025 $2,103
Food & beverage: $2,103
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 19 | $316 |
| Otsuka America Pharmaceutical, Inc. | 16 | $313 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $274 |
| ABBVIE INC. | 17 | $257 |
| Supernus Pharmaceuticals, Inc. | 12 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $214 |
| Lundbeck LLC | 12 | $209 |
| Vanda Pharmaceuticals Inc. | 6 | $129 |
| Corium, LLC | 2 | $46 |
| Almatica Pharma LLC | 2 | $33 |
Products named: REXULTI, Auvelity, CAPLYTA, VRAYLAR, Qelbree, TRINTELLIX, FANAPT, Azstarys.
Industry payments across GA — which companies pay providers there.
